Scarica l'app Stockscreener
3.88
22.55%
-1.13
Dopo l'orario di chiusura:
3.97
0.09
+2.32%
Acurx Pharmaceuticals Inc Borsa (ACXP) Ultime notizie
What's Going On With Acurx Pharmaceuticals Stock Today? - Sahm
Acurx Pharmaceuticals (ACXP) Stock Rockets 218% as Phase 3 CDI Trial Gets Green Light - MEXC
Acurx Pharmaceuticals, Inc. (ACXP) Stock: Reduces Net Loss While Expanding Ibezapolstat Clinical Program - parameter.io
Acurx Pharmaceuticals (ACXP) Stock Explodes 218% on CDI Clinical Trial Breakthrough - MEXC
Acurx Pharma Stock Dips 9% Amid Market Volatility - timothysykes.com
ACXP: Strong phase II results and new rCDI trial drive momentum amid improved financials - TradingView
Earnings call transcript: Acurx Pharmaceuticals Q4 2025 reveals cash boost and R&D progress - Investing.com
ACXP: Ibezapolstat progresses toward first-in-class status for rCDI, with strong results and new trials - TradingView
Acurx Pharmaceuticals (ACXP) Stock Soars 218% Following Phase 3 CDI Trial Approval - parameter.io
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Resigns with New to The Street for Long-Form Interviews, National TV Commercials, Earned Media, and Accredited Investor Events - Times Record News
Acurx Pharmaceuticals stock gains over 3% on new rCDI trial launch - Investing.com
Earnings Scheduled For March 13, 2026 - Benzinga
ACXP: Cash up, losses down, and ibezapolstat advances toward pivotal Phase 3 trials - TradingView
Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update - Yahoo Finance
Why Is Acurx Pharmaceuticals Stock Falling Thursday? - Sahm
Pullback Watch: What are the risks of holding Acurx Pharmaceuticals Inc2026 Movers & Weekly Top Gainers Trade List - baoquankhu1.vn
Acurx Pharmaceuticals Stock (ACXP) Explodes 218% as New Trial Moves Forward on 96% Cure Rate - TipRanks
Acurx Pharmaceuticals 10-K: $0 Revenue, Net Loss $7.97M - TradingView
Acurx Pharmaceuticals (ACXP) highlights ibezapolstat CDI data and $1B market - Stock Titan
Acurx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Why is Acurx Pharmaceuticals stock falling Thursday? - MSN
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Best Pharmaceutical Stocks To Follow NowMarch 11th - MarketBeat
Why Is Acurx Pharmaceuticals Stock Up Over 105% Today? - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Acurx Launches New Trial Amidst Promising Developments in C. Difficile Treatment - StocksToTrade
Acurx Pharma shares rise by 29% on new trial for breakthrough antibiotic ‘ibezapolstat’ - Mugglehead Investment Magazine
Acurx Launches Revolutionary Trials for C. difficile Drug - timothysykes.com
Acurx Pharmaceuticals Inc expected to post a loss of $1.01 a shareEarnings Preview - TradingView
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Will Acurx Pharma's Ibezapolstat Redefine Treatment For C. Diff Infection? - RTTNews
Acurx Pharma shares rise by 29% after launching trial for breakthrough antibiotic 'ibezapolstat' - Mugglehead Investment Magazine
ACXP Acurx Pharmaceuticals NASDAQ 10 Mar 2026: Ibezapolstat trial headlines earnings - Meyka
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Acurx Pharmaceuticals Expands Ibezapolstat Trials in Europe - StocksToTrade
Acurx Pharmaceuticals (ACXP.US) will release its earnings report before the market opens on March 13. - 富途牛牛
Acurx Launches New Ibezapolstat Clinical Trials for Recurrent C. difficile Infection (rCDI) with Potential to Transform CDI Treatment and Prevention - Minichart
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Acurx Advances Ibezapolstat Program for Recurrent C. difficile - TipRanks
Acurx tests one-drug approach in 20-patient C. diff relapse trial - Stock Titan
Acurx Pharmaceuticals (ACXP) secures new US patent for DNA polymerase IIIC inhibitors - MSN
Aug Closing: What are the risks of holding Acurx Pharmaceuticals Inc2025 Dividend Review & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
How Acurx Pharmaceuticals Inc. stock performs in weak economy2025 Fundamental Recap & Risk Controlled Daily Plans - Naître et grandir
Acurx Pharmaceuticals (ACXP) Expected to Announce Earnings on Friday - Defense World
ACXP SEC FilingsAcurx Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ACXP Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ACXP Should I Buy - Intellectia AI
Aug PostEarnings: What is the dividend yield of Acurx Pharmaceuticals Inc2025 Biggest Moves & Safe Entry Zone Identification - baoquankhu1.vn
Acurx Pharmaceuticals (ACXP) Secures New US Patent for DNA Polymerase IIIC Inhibitors - Finviz
Is Acurx Pharmaceuticals Inc. stock trading at a premium valuation2025 Support & Resistance & Precise Swing Trade Alerts - mfd.ru
Can Acurx Pharmaceuticals Inc. keep up with sector leaders2025 Fundamental Recap & AI Enhanced Trading Signals - mfd.ru
What is Acurx Pharmaceuticals Inc. s 5 year growth outlookQuarterly Profit Report & AI Driven Stock Price Forecasts - mfd.ru
ACXP PE Ratio & Valuation, Is ACXP Overvalued - Intellectia AI
Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update - Yahoo Finance
Acurx Pharmaceuticals Approaches Critical Phase 3 Trial Launch - AD HOC NEWS
What Wall Street predicts for Acurx Pharmaceuticals Inc. stock priceWeekly Stock Analysis & Safe Entry Momentum Stock Tips - mfd.ru
Acurx patent backs new antibiotics for C. diff and MRSA - Stock Titan
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):